Screener
Capricor Therapeutics CAPR Business Segments — Net Income Loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Capricor Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 5:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-060382
| REVENUE / TOTAL REVENUE | Three Months Ended March 31, 2026 / — | Three Months Ended March 31, 2025 / — |
|---|---|---|
| TOTAL OTHER INCOME (EXPENSE) | 2,831,508 | 591,354 |
| LOSS BEFORE INCOME TAXES | (33,941,345) | (24,391,594) |
| (Provision for) benefit from income taxes | — | — |
| NET LOSS | $(33,941,345) | $(24,391,594) |
| OTHER COMPREHENSIVE INCOME (LOSS) | ||
| Net unrealized gain (loss) on marketable securities | (536,881) | 784,972 |
| COMPREHENSIVE LOSS | $(34,478,226) | $(23,606,622) |
| Net loss per share, basic and diluted | $(0.59) | $(0.53) |
Item 1. Financial Statements.
FAQ
- What is Capricor Therapeutics's business segments — net income loss?
- Capricor Therapeutics (CAPR) reported business segments — net income loss of -$33.94M in Q1 2026.
- How has Capricor Therapeutics's business segments — net income loss changed year-over-year?
- Capricor Therapeutics's business segments — net income loss decreased by 39.2% year-over-year, from -$24.39M to -$33.94M.
- What does business segments — net income loss mean?
- This represents the final bottom-line profit or loss for the business segment after all expenses, taxes, and non-operating items have been deducted. It is the definitive measure of the company's financial performance for the period. For development-stage biotech companies, this typically reflects the net cash burn required to sustain operations.
Ask your AI about Capricor Therapeutics's business segments — net income loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude